The relationship between the peroxisome proliferator-activated receptor gamma 2 gene polymorphism, lipids and adipokines in patients with major depression;Majör depresyonlu hastalarda peroksizom çoǧaltici-aktive edici reseptör gama 2 gen polimorfizmi, lipidler ve adipokinlerle ilişkisi

Turkiye Klinikleri Journal of Medical Sciences

Volumn 31, Issue 5, 2011, Pages 1065-1072

  Aliyazicioglu, Rezzan ^a   Deǧer, Orhan ^a   Vanizor Kural, Birgül ^a   Hocaoǧlu, Çiçek ^b   Çolak, Meltem ^c   Balaban Yücesan, Fulya ^c  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b RECEP TAYYIP ERDOGAN UNIVERSITY   (Turkey)

^c GUMUSHANE UNIVERSITY   (Turkey)

Author keywords

Adipokines; Lipids; Major depressive disorder; single nucleotide polymorphisms; PPAR gamma

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; TRIACYLGLYCEROL;

ADULT; AGED; ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NEPHELOMETRY; OBESITY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2 GENE; RECEPTOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 80054760148     PISSN: 13000292     EISSN: None     Source Type: Journal    
DOI: 10.5336/medsci.2010-20010     Document Type: Article

References (33)

1. rd ed. Washington DC: American Psychiatric Press; 1994. p.943.
2. Aydemir Ö, Ergün H, Soygür H, Kesebir S, Tulunay C. [Quality of life in major depressive disorder: a cross-sectional study]. Turkish Journal of Psychiatry 2009;20(3):205-12.
3. Sato K, Fukao K, Seki Y, Akiba Y. Expression of the chicken peroxisome proliferator-activated receptor-gamma gene is influenced by aging, nutrition, and agonist administration. Poult Sci 2004;83(8):1342-7.
4. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996;87(3): 377-89.
5. Abdelrahman M, Sivarajah A, Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 2005;65(4):772-81.
6. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994;79(7): 1147-56.
7. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998;339(14): 953-9.
8. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402(6764):880-3.
9. Fajas L, Auboeuf D, Raspé E, Schoonjans K, Lefebvre AM, Saladin R, et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997;272(30): 18779-89.
10. FaIas L, Fruchart JC, Auwerx J. PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett 1998;438(1-2):55-60.
11. Swarbrick MM, Chapman CM, McQuillan BM, Hung J, Thompson PL, Bellby JP. A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. Eur J Endocrinol 2001;144(3):277-82.
12. Vidal-Puig AJ, Considine RV, Jimenez-Liñan M, Werman A, Pories WJ, Caro JF, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticolds. J Clin Invest 1997;99(10): 2416-22.
13. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 1997; 241(2):270-4.
14. Stumvoll M, Haring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 2002;51(8):2341-7.
15. Cardona F, Morcillo S, Gonzalo-Marín M, Garrido-Sanchez L, Macias-Gonzalez M, Tinahones FJ. Pro12Ala sequence variant of the PPARG gene is associated with postprandial hypertriglyceridemia in non-E3/E3 patients with the metabolic syndrome. Clin Chem 2006;52(10):1920-5.
16. Yamashita S, Nakamura T, Shimomura I, Nishida M, Yoshida S, Kotani K, et al. Insulin resistance and body fat distribution. Diabetes Care 1996;19(3):287-91.
17. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003;149(4):331-5.
18. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395(6704):763-70.
19. Yang B, Brown KK, Chen L, Carrick KM, Clifton LG, McNulty JA, et al. Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats. BMC Pharmacol 2004;4:23.
20. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50(9):2094-9.
21. Memisoglu A, Hu FB, Hankinson SE, Manson JE, De Vivo I, Willett WC, et al. Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Hum Mol Genet 2003;12(22):2923-9.
22. Tai ES, Corella D, Deurenberg-Yap M, Adiconis X, Chew SK, Tan CE, et al. Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res 2004;45(4):674-85.
23. Ji-Rong Y, Bi-Rong D, Chang-Quan H, Zhen-Chan L, Hong-Me W, Yan-Ling Z, et al. Pro12Ala polymorphism in PPARgamma2 associated with depression in Chinese nonagenarians/centenarians. Arch Med Res 2009; 40(5):411-5.
24. Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deeb SS, et al. Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 1999;84(10):3708-12.
25. Deeb SS, Fajas L, Nemoto M, PihlalamaÈki J, MykkaÈnen L, Kuusisto J, et al. Pro12Ala substitution in PPAR 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genet 1998;20(3):284-7.
26. Melrhaeghe A, Fajas L, Helbecque N, Cottel D, Auwerx J, Deeb SS, et al. Impact of the Peroxisome Proliferator Activated Receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 2000;24(2):195-9.
27. Kallen CB, Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A 1996;93(12):5793-6.
28. Zhang B, Graziano MP, Doebber TW, Leibowitz MD, White-Carrington S, Szalkowski DM, et al. Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 1996;271(16):9455-9.
29. Steppan CM, Balley ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409(6818):307-12.
30. Weber-Hamann B, Kratzsch J, Kopf D, Lederbogen F, Gilles M, Heuser I, et al. Resistin and adiponectin in major depression: the association with free cortisol and effects of antidepressant treatment. J Psychiatr Res 2007; 41(3-4):344-50.
31. Way JM, Görgün CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2001;276 (28):25651-3.
32. Hivert MF, Sullivan LM, Fox CS, Nathan DM, D'Agostino RB Sr, Wilson PW, et al. Association of adiponectin, resistin and TNF{alpha} with insulin resistance. J Clin Endocrinol Metab 2008;93(8): 3165-72.
33. Haseeb A, Iliyas M, Chakrabarti S, Farooqui AA, Nalk SR, Ghosh S, et al. Single-nucleotide polymorphisms in peroxisome proliferator-activated receptor and their association with plasma levels of resistin and the metabolic syndrome in a South Indian population. J Biosci 2009;34(3):405-14.